Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGB-BS02
- Development stage
- Preclinical
- Lead developer
- Sanegene Bio
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SGB-BS02 is an investigational RNA interference (RNAi) therapeutic developed by Sanegene Bio (Suzhou Shengyin Biopharmaceutical) for the treatment of dyslipidemia. It is designed to simultaneously target Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Lipoprotein(a) (LPA). By utilizing small interfering RNA (siRNA) to silence the expression of these two key genetic drivers of cardiovascular risk, SGB-BS02 aims to lower both LDL cholesterol and Lp(a) levels. The program is currently in the IND-enabling phase and utilizes the company's proprietary LEAD (Liver-targeting Efficient siRNA Delivery) platform for liver-specific delivery.
- Other names
- SGB-BS02SGB-BS-02SGB-BS 02
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)ANGPTL3 (Angiopoietin-like protein 3)
Beyond the preview
Go deeper on SGB-BS02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGB-BS02.